ANTHEM BIOSCIENCES IPO
IPO lock-ins worth $20 billion to hit stock market in next 3 months
Between August 25 and November 27, 2025, 57 companies will see pre-listing shareholder lock-ins expire, totaling nearly USD 20 billion. Major unlocks span one-, three-, and six-month schedules, with key stocks including Ather Energy, JSW Cement, and Brigade Hotel Ventures, potentially impacting market activity.
Is the IPO market the new gold? 2025 listings outshine Nifty with 4X returns
Despite muted returns in broader markets, India’s IPO space has outperformed in 2025, with 27 of 30 listings trading above issue price and delivering average gains of 25%. Strong retail demand, sectoral variety, and attractive valuations are driving momentum in the primary market.
Anthem Biosciences shares list at 27% premium over IPO price
Anthem Biosciences share price listed at a premium after its IPO. The IPO was subscribed 67.4 times. Qualified institutional buyers showed strong interest. The company raised Rs 3,396 crore. Anthem operates across the drug development lifecycle. In FY25, revenue rose 30% to Rs 1,930 crore. Net profit grew 23% to Rs 451 crore. All eyes are on Anthem's market performance.
Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
Anthem Biosciences share price: Anthem’s IPO did not include a fresh issue, with all proceeds going to existing shareholders. Prior to the IPO opening, anchor investors had already invested Rs 1,016 crore.
Anthem Biosciences IPO: What GMP signals ahead of listing on Monday
Anthem Biosciences will debut on stock exchanges on Monday, July 21, with grey market signals suggesting a potential 29% listing gain over its Rs 570 IPO price. The Rs 3,395 crore OFS-only issue closed on July 16 with strong demand, garnering 67.42 times overall subscription, led by QIBs (192.80x), NIIs (44.70x), and retail (5.98x).
- Go To Page 1
Q1 earnings, FII action among 8 factors that’ll steer D-Street this week
Indian equities ended the week lower, with the Nifty slipping 0.7%. On Friday, it declined 143 points to close at 24,968. Despite holding above its 50-EMA, the index remained under pressure. Analysts flagged 24,900 as a key support; a breach could trigger further downside. Market direction this week hinges on crucial domestic and global cues.
Anthem Biosciences IPO subscribed 4x on last day; Check GMP, and other key details
Anthem Biosciences IPO GMP: The IPO attracted strong interest, receiving bids for 17.66 crore shares against 4.4 crore shares on offer. Non-institutional investors (NIIs) led the demand, subscribing 12.37 times their allotted quota. The retail segment saw 2.38 times subscription, while qualified institutional buyers (QIBs) subscribed to 60% of their portion.
Anthem Biosciences IPO allotment out today; GMP strong ahead of listing
Anthem Biosciences IPO allotment date: The allotment for Anthem Biosciences IPO is now complete. Investors can check their status on KFin Technologies website. The IPO saw significant oversubscription, especially from institutional buyers. Refunds for those not allotted will begin soon. Shares will be credited to demat accounts on the same day. Anthem Biosciences is set to debut on the stock market next week.
Anthem Biosciences IPO subscribed 2x on day 2; Check GMP, and other key details
Anthem Biosciences' IPO witnessed strong investor interest, being oversubscribed 2.08 times on Day 2, driven by NIIs. Brokerages recommend subscribing, citing the company's robust position and high-margin business model. The IPO, valued at a P/E ratio of 71x, closes on July 16, offering a compelling long-term growth opportunity in the CRDMO segment.
NSE ranks fourth in global IPO table with $5.51 billion fundraising: S&P
India's NSE ranked 4th globally in IPO fundraising in H1 2025, raising $5.51 billion. Despite early volatility, 119 IPOs raised Rs 51,150 crore. A strong pipeline, economic momentum, and policy support may drive robust activity in H2, especially in fintech and industrial tech sectors.
Anthem Biosciences' Rs 3,395 crore IPO opens for subscription. Should you bid?
Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band of Rs 540–570 per share, boasts integrated capabilities in both small and large molecules. Analysts recommend subscribing, citing its strong market position, revenue visibility, and high-margin business model.
Is Anthem Biosciences IPO a risky bet for investors?
Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit have increased, the company faces geographical and client concentration risks. Despite a high P/E ratio compared to peers, investors with a high-risk tolerance may find the IPO appealing.
IPO Calendar: 3 new issues eye Rs 3,600 crore as primary market momentum continues
Three IPOs—Anthem Biosciences, Spunweb Nonwoven, and Monika Alcobev—aim to raise over Rs 3,600 crore in the week starting July 14. With strong retail interest and sectoral momentum, investor focus remains high. Upcoming listings and grey market trends will guide sentiment amid keen interest in pharma, textiles, and liquor distribution.
Anthem Biosciences sets IPO price band at Rs 540-570/share
Anthem Biosciences is launching its IPO from July 14-16. The price is fixed between Rs 540 to Rs 570. The IPO aims to raise Rs 3,395 crore through offer-for-sale. The company will use the funds for expansion. Anthem's revenue increased by 30% in FY25. The IPO will be listed on BSE and NSE on July 21.
Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14
Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CRDMO firm provides integrated drug development and manufacturing services across advanced technology platforms and modalities.
India's IPO market loses steam on global market jitters
Several Indian companies are delaying their initial public offerings. This is due to weak investor sentiment and global economic uncertainty. Avanse Financial and Anthem Biosciences are among those postponing plans. Geopolitical tensions and global trade frictions are contributing factors. The market debut of Ather Energy will be a test of investor appetite.
Four companies receive approval from Sebi for IPOs
The regulator issued its final observations on the draft papers last week. When a company receives a final observation from Sebi, it's a signal from the regulator to go ahead with the IPO process.
BlueStone Jewellery, Anthem Biosciences, Aye Finance and GK Energy get Sebi nod to launch IPO, to collectively raise over Rs 6,300 crore
BlueStone Jewellery, Anthem Biosciences, Aye Finance, and GK Energy have received SEBI's approval for their IPOs. BlueStone aims to raise ₹1,000 crore through a fresh issue and an offer for sale. Anthem Biosciences plans to raise ₹3,395 crore, while Aye Finance seeks ₹1,450 crore to support MSME lending.
Indo Farm Equipment IPO Day 2: Check subscription status, GMP, price band and other details
The IPO of Indo Farm Equipment received strong investor response on its opening day, getting subscribed 6.94 times. The offering included both fresh shares and shares from the promoter. The funds will be used for pre-payment of borrowings, investment in a subsidiary, and general purposes. Shares are expected to list on January 7.
Anthem Biosciences files DRHP for Rs 3,395 crore IPO
Anthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True North.
Anthem Biosciences files DRHP for Rs 3,395 crore IPO
Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors. Proceeds from the sale will go to the selling shareholders.
Anthem Biosciences appoints JM Financial, Citi, JP Morgan as bankers for IPO
Anthem Biosciences has selected JM Financial as the lead banker for its IPO, along with Citi and JP Morgan. The company plans to raise Rs 3,300 crore. Anthem's financials showed a turnover of Rs 1,057 crore and a net profit of Rs 385 crore for the fiscal year ending March 2023.
Investment banking industry struggles to attract talent amid exodus of senior professionals
Of the 300 middle and senior-level moves in investment banking in the last 12 months, about 65% have joined other domains, from startups to large corporations, according to data from executive search firm Native. At the same time, for several top investment banks, talent has become hard to come by across levels.
Pharma fever grips dealmakers despite M&A spike and a frenzy IPO year
More than a dozen top bankers moved to strategic and M&A roles in pharmaceutical companies, spearheading mergers and acquisition as well as fundraising plans. They included Nitin Tandon, who joined as head business development, Asia Pacific, at Johnson & Johnson from Credit Suisse.
Load More
